Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 03:14PM ET
2.84
Dollar change
+0.09
Percentage change
3.09
%
IndexRUT P/E- EPS (ttm)-6.16 Insider Own26.96% Shs Outstand29.93M Perf Week3.09%
Market Cap95.34M Forward P/E- EPS next Y-2.13 Insider Trans-0.11% Shs Float24.56M Perf Month0.18%
Income-179.05M PEG- EPS next Q-0.70 Inst Own28.05% Short Float10.14% Perf Quarter8.62%
Sales1.38M P/S69.09 EPS this Y58.67% Inst Trans-5.10% Short Ratio1.62 Perf Half Y9.46%
Book/sh-1.89 P/B- EPS next Y16.39% ROA-128.10% Short Interest2.49M Perf Year-86.60%
Cash/sh1.94 P/C1.46 EPS next 5Y- ROE-1766.94% 52W Range1.91 - 29.56 Perf YTD-3.90%
Dividend Est.- P/FCF- EPS past 5Y-35.97% ROI-402.10% 52W High-90.41% Beta0.40
Dividend TTM- Quick Ratio2.57 Sales past 5Y53.60% Gross Margin-19.64% 52W Low48.43% ATR (14)0.20
Dividend Ex-Date- Current Ratio2.65 EPS Y/Y TTM-4.12% Oper. Margin-12053.26% RSI (14)52.78 Volatility7.09% 6.28%
Employees74 Debt/Eq- Sales Y/Y TTM268.00% Profit Margin-12974.86% Recom1.80 Target Price6.30
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q61.29% Payout- Rel Volume0.23 Prev Close2.75
Sales Surprise-49.39% EPS Surprise17.09% Sales Q/Q57.98% EarningsMar 12 BMO Avg Volume1.54M Price2.84
SMA204.02% SMA50-1.82% SMA200-30.85% Trades Volume311,517 Change3.09%
Date Action Analyst Rating Change Price Target Change
Feb-21-24Downgrade UBS Buy → Neutral $9 → $4
Aug-15-23Downgrade Mizuho Buy → Neutral $40 → $4
Jul-17-23Downgrade Guggenheim Buy → Neutral
Mar-10-23Downgrade Jefferies Buy → Hold $20 → $22
Dec-01-22Upgrade Goldman Sell → Neutral $16
Jul-07-22Initiated Mizuho Buy $19
Apr-06-22Reiterated BofA Securities Buy $80
Nov-15-21Downgrade Goldman Neutral → Sell $55 → $24
Apr-09-21Initiated Berenberg Buy $75
Feb-01-21Initiated UBS Buy $99
Today 07:00AM
Apr-10-24 07:00AM
Mar-25-24 07:00AM
Mar-15-24 07:00AM
Mar-13-24 08:57AM
09:48PM Loading…
Mar-12-24 09:48PM
07:00AM
Mar-07-24 02:52PM
Mar-01-24 07:00AM
Feb-22-24 12:58PM
Feb-14-24 08:30AM
Feb-13-24 09:00AM
Feb-12-24 07:14AM
Feb-09-24 09:05AM
Feb-08-24 04:01PM
07:00AM Loading…
Feb-06-24 07:00AM
Feb-05-24 07:00AM
Dec-12-23 07:00AM
Dec-11-23 07:00AM
Dec-01-23 07:29PM
Nov-30-23 07:00AM
Nov-24-23 06:40AM
Nov-15-23 02:23PM
02:27AM
Nov-14-23 07:52AM
07:00AM
Nov-08-23 07:00AM
Nov-06-23 07:00AM
Oct-31-23 07:00AM
Oct-30-23 07:00AM
09:18AM Loading…
Oct-25-23 09:18AM
07:00AM
Oct-17-23 10:26AM
Oct-10-23 09:45AM
07:00AM
Oct-04-23 07:00AM
Sep-28-23 05:35PM
Aug-29-23 07:30AM
Aug-17-23 10:30AM
Aug-15-23 05:43PM
09:59AM
Aug-14-23 11:04PM
12:44PM
12:01PM
07:24AM
07:21AM
07:06AM
07:00AM
Jul-31-23 07:00AM
Jul-07-23 08:16AM
Jul-05-23 10:20AM
Jun-29-23 04:12PM
11:33AM
06:04AM
06:00AM
06:00AM
Jun-15-23 09:46PM
Jun-02-23 06:20AM
Jun-01-23 07:00AM
May-25-23 04:03PM
03:10PM
12:40PM
07:00AM
May-16-23 07:00AM
May-11-23 03:13PM
10:20AM
May-09-23 02:03AM
May-08-23 04:54PM
04:07PM
09:25AM
07:00AM
May-04-23 08:00AM
May-02-23 07:00AM
Apr-24-23 07:00AM
Mar-22-23 08:21AM
Mar-14-23 04:15PM
Mar-11-23 09:25AM
Mar-10-23 02:32AM
Mar-09-23 07:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Feb-14-23 09:50AM
Feb-13-23 05:00PM
Feb-08-23 02:27PM
07:00AM
Jan-27-23 07:00AM
Jan-11-23 07:00AM
Dec-27-22 07:34AM
Dec-22-22 07:00AM
Dec-19-22 07:00AM
Dec-15-22 04:45PM
Dec-06-22 09:53AM
Dec-02-22 06:02PM
Dec-01-22 07:00AM
Nov-30-22 07:00AM
Nov-20-22 09:45AM
Nov-14-22 07:00AM
06:22AM
Nov-10-22 07:00AM
Oct-27-22 07:00AM
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehta VimalCEO and PresidentApr 04 '24Sale2.625,26813,82343,564Apr 08 07:32 PM
Steinhart Richard IChief Financial OfficerApr 04 '24Sale2.631,0692,8174,765Apr 08 07:32 PM
Yocca FrankChief Scientific OfficerApr 04 '24Sale2.631,0672,81212,763Apr 08 07:30 PM
Rodriguez JavierSee RemarksApr 04 '24Sale2.641,0122,6677,672Apr 08 07:30 PM
Wiley Matthew T.CHIEF COMMERCIAL OFFICERApr 04 '24Sale2.641,0082,6562,992Apr 08 07:31 PM
O'Neill VincentSee RemarksApr 04 '24Sale2.621654325,408Apr 08 07:32 PM
Mehta VimalCEO and PresidentJun 16 '23Option Exercise0.4130,00012,30069,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 16 '23Sale20.1830,000605,50139,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 15 '23Option Exercise0.4130,00012,30069,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentJun 15 '23Sale21.5430,000646,22639,903Jun 16 06:40 PM
Mehta VimalCEO and PresidentMay 22 '23Sale25.796,500167,64137,294May 24 04:37 PM
Steinhart Richard IChief Financial OfficerMay 15 '23Sale27.175,000135,8641,500May 16 08:32 PM
Rodriguez JavierSee RemarksMay 15 '23Sale27.321,78548,7654,350May 16 08:29 PM